FKBP12.6 protects heart from AngII-induced hypertrophy through inhibiting Ca2+/calmodulin-mediated signalling pathways in vivo and in vitro

Yun Fei Xiao, Zhi Xiong Zeng, Xiao Hui Guan, Ling Fang Wang, Chan Juan Wang, Huidong Shi, Weinian Shou, Ke Yu Deng, Hong Bo Xin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We previously observed that disruption of FK506-binding protein 12.6 (FKBP12.6) gene resulted in cardiac hypertrophy in male mice. Studies showed that overexpression of FKBP12.6 attenuated thoracic aortic constriction (TAC)-induced cardiac hypertrophy in mice, whereas the adenovirus-mediated overexpression of FKBP12.6 induced hypertrophy and apoptosis in cultured neonatal cardiomyocytes, indicating that the role of FKBP12.6 in cardiac hypertrophy is still controversial. In this study, we aimed to investigate the roles and mechanisms of FKBP12.6 in angiotensin II (AngII)-induced cardiac hypertrophy using various transgenic mouse models in vivo and in vitro. FKBP12.6 knockout (FKBP12.6−/−) mice and cardiac-specific FKBP12.6 overexpressing (FKBP12.6 TG) mice were infused with AngII (1500 ng/kg/min) for 14 days subcutaneously by implantation of an osmotic mini-pump. The results showed that FKBP12.6 deficiency aggravated AngII-induced cardiac hypertrophy, while cardiac-specific overexpression of FKBP12.6 prevented hearts from the hypertrophic response to AngII stimulation in mice. Consistent with the results in vivo, overexpression of FKBP12.6 in H9c2 cells significantly repressed the AngII-induced cardiomyocyte hypertrophy, seen as reductions in the cell sizes and the expressions of hypertrophic genes. Furthermore, we demonstrated that the protection of FKBP12.6 on AngII-induced cardiac hypertrophy was involved in reducing the concentration of intracellular Ca2+ ([Ca2+]i), in which the protein significantly inhibited the key Ca2+/calmodulin-dependent signalling pathways such as calcineurin/cardiac form of nuclear factor of activated T cells 4 (NFATc4), calmodulin kinaseII (CaMKII)/MEF-2, AKT/Glycogen synthase kinase 3β (GSK3β)/NFATc4 and AKT/mTOR signalling pathways. Our study demonstrated that FKBP12.6 protects heart from AngII-induced cardiac hypertrophy through inhibiting Ca2+/calmodulin-mediated signalling pathways.

Original languageEnglish (US)
Pages (from-to)3638-3651
Number of pages14
JournalJournal of Cellular and Molecular Medicine
Volume22
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Tacrolimus Binding Proteins
Calmodulin
Angiotensin II
Hypertrophy
Cardiomegaly
NFATC Transcription Factors
Cardiac Myocytes
Glycogen Synthase Kinase 3
Protein Deficiency
Calcineurin
Cell Size
Adenoviridae
Constriction
Knockout Mice

Keywords

  • Ca signalling
  • FKBP12.6
  • angiotensin II
  • cardiac hypertrophy
  • transgenic mice

ASJC Scopus subject areas

  • Molecular Medicine
  • Cell Biology

Cite this

FKBP12.6 protects heart from AngII-induced hypertrophy through inhibiting Ca2+/calmodulin-mediated signalling pathways in vivo and in vitro. / Xiao, Yun Fei; Zeng, Zhi Xiong; Guan, Xiao Hui; Wang, Ling Fang; Wang, Chan Juan; Shi, Huidong; Shou, Weinian; Deng, Ke Yu; Xin, Hong Bo.

In: Journal of Cellular and Molecular Medicine, Vol. 22, No. 7, 01.07.2018, p. 3638-3651.

Research output: Contribution to journalArticle

Xiao, Yun Fei ; Zeng, Zhi Xiong ; Guan, Xiao Hui ; Wang, Ling Fang ; Wang, Chan Juan ; Shi, Huidong ; Shou, Weinian ; Deng, Ke Yu ; Xin, Hong Bo. / FKBP12.6 protects heart from AngII-induced hypertrophy through inhibiting Ca2+/calmodulin-mediated signalling pathways in vivo and in vitro. In: Journal of Cellular and Molecular Medicine. 2018 ; Vol. 22, No. 7. pp. 3638-3651.
@article{772925a307de4eb6811c8e22a3e00882,
title = "FKBP12.6 protects heart from AngII-induced hypertrophy through inhibiting Ca2+/calmodulin-mediated signalling pathways in vivo and in vitro",
abstract = "We previously observed that disruption of FK506-binding protein 12.6 (FKBP12.6) gene resulted in cardiac hypertrophy in male mice. Studies showed that overexpression of FKBP12.6 attenuated thoracic aortic constriction (TAC)-induced cardiac hypertrophy in mice, whereas the adenovirus-mediated overexpression of FKBP12.6 induced hypertrophy and apoptosis in cultured neonatal cardiomyocytes, indicating that the role of FKBP12.6 in cardiac hypertrophy is still controversial. In this study, we aimed to investigate the roles and mechanisms of FKBP12.6 in angiotensin II (AngII)-induced cardiac hypertrophy using various transgenic mouse models in vivo and in vitro. FKBP12.6 knockout (FKBP12.6−/−) mice and cardiac-specific FKBP12.6 overexpressing (FKBP12.6 TG) mice were infused with AngII (1500 ng/kg/min) for 14 days subcutaneously by implantation of an osmotic mini-pump. The results showed that FKBP12.6 deficiency aggravated AngII-induced cardiac hypertrophy, while cardiac-specific overexpression of FKBP12.6 prevented hearts from the hypertrophic response to AngII stimulation in mice. Consistent with the results in vivo, overexpression of FKBP12.6 in H9c2 cells significantly repressed the AngII-induced cardiomyocyte hypertrophy, seen as reductions in the cell sizes and the expressions of hypertrophic genes. Furthermore, we demonstrated that the protection of FKBP12.6 on AngII-induced cardiac hypertrophy was involved in reducing the concentration of intracellular Ca2+ ([Ca2+]i), in which the protein significantly inhibited the key Ca2+/calmodulin-dependent signalling pathways such as calcineurin/cardiac form of nuclear factor of activated T cells 4 (NFATc4), calmodulin kinaseII (CaMKII)/MEF-2, AKT/Glycogen synthase kinase 3β (GSK3β)/NFATc4 and AKT/mTOR signalling pathways. Our study demonstrated that FKBP12.6 protects heart from AngII-induced cardiac hypertrophy through inhibiting Ca2+/calmodulin-mediated signalling pathways.",
keywords = "Ca signalling, FKBP12.6, angiotensin II, cardiac hypertrophy, transgenic mice",
author = "Xiao, {Yun Fei} and Zeng, {Zhi Xiong} and Guan, {Xiao Hui} and Wang, {Ling Fang} and Wang, {Chan Juan} and Huidong Shi and Weinian Shou and Deng, {Ke Yu} and Xin, {Hong Bo}",
year = "2018",
month = "7",
day = "1",
doi = "10.1111/jcmm.13645",
language = "English (US)",
volume = "22",
pages = "3638--3651",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - FKBP12.6 protects heart from AngII-induced hypertrophy through inhibiting Ca2+/calmodulin-mediated signalling pathways in vivo and in vitro

AU - Xiao, Yun Fei

AU - Zeng, Zhi Xiong

AU - Guan, Xiao Hui

AU - Wang, Ling Fang

AU - Wang, Chan Juan

AU - Shi, Huidong

AU - Shou, Weinian

AU - Deng, Ke Yu

AU - Xin, Hong Bo

PY - 2018/7/1

Y1 - 2018/7/1

N2 - We previously observed that disruption of FK506-binding protein 12.6 (FKBP12.6) gene resulted in cardiac hypertrophy in male mice. Studies showed that overexpression of FKBP12.6 attenuated thoracic aortic constriction (TAC)-induced cardiac hypertrophy in mice, whereas the adenovirus-mediated overexpression of FKBP12.6 induced hypertrophy and apoptosis in cultured neonatal cardiomyocytes, indicating that the role of FKBP12.6 in cardiac hypertrophy is still controversial. In this study, we aimed to investigate the roles and mechanisms of FKBP12.6 in angiotensin II (AngII)-induced cardiac hypertrophy using various transgenic mouse models in vivo and in vitro. FKBP12.6 knockout (FKBP12.6−/−) mice and cardiac-specific FKBP12.6 overexpressing (FKBP12.6 TG) mice were infused with AngII (1500 ng/kg/min) for 14 days subcutaneously by implantation of an osmotic mini-pump. The results showed that FKBP12.6 deficiency aggravated AngII-induced cardiac hypertrophy, while cardiac-specific overexpression of FKBP12.6 prevented hearts from the hypertrophic response to AngII stimulation in mice. Consistent with the results in vivo, overexpression of FKBP12.6 in H9c2 cells significantly repressed the AngII-induced cardiomyocyte hypertrophy, seen as reductions in the cell sizes and the expressions of hypertrophic genes. Furthermore, we demonstrated that the protection of FKBP12.6 on AngII-induced cardiac hypertrophy was involved in reducing the concentration of intracellular Ca2+ ([Ca2+]i), in which the protein significantly inhibited the key Ca2+/calmodulin-dependent signalling pathways such as calcineurin/cardiac form of nuclear factor of activated T cells 4 (NFATc4), calmodulin kinaseII (CaMKII)/MEF-2, AKT/Glycogen synthase kinase 3β (GSK3β)/NFATc4 and AKT/mTOR signalling pathways. Our study demonstrated that FKBP12.6 protects heart from AngII-induced cardiac hypertrophy through inhibiting Ca2+/calmodulin-mediated signalling pathways.

AB - We previously observed that disruption of FK506-binding protein 12.6 (FKBP12.6) gene resulted in cardiac hypertrophy in male mice. Studies showed that overexpression of FKBP12.6 attenuated thoracic aortic constriction (TAC)-induced cardiac hypertrophy in mice, whereas the adenovirus-mediated overexpression of FKBP12.6 induced hypertrophy and apoptosis in cultured neonatal cardiomyocytes, indicating that the role of FKBP12.6 in cardiac hypertrophy is still controversial. In this study, we aimed to investigate the roles and mechanisms of FKBP12.6 in angiotensin II (AngII)-induced cardiac hypertrophy using various transgenic mouse models in vivo and in vitro. FKBP12.6 knockout (FKBP12.6−/−) mice and cardiac-specific FKBP12.6 overexpressing (FKBP12.6 TG) mice were infused with AngII (1500 ng/kg/min) for 14 days subcutaneously by implantation of an osmotic mini-pump. The results showed that FKBP12.6 deficiency aggravated AngII-induced cardiac hypertrophy, while cardiac-specific overexpression of FKBP12.6 prevented hearts from the hypertrophic response to AngII stimulation in mice. Consistent with the results in vivo, overexpression of FKBP12.6 in H9c2 cells significantly repressed the AngII-induced cardiomyocyte hypertrophy, seen as reductions in the cell sizes and the expressions of hypertrophic genes. Furthermore, we demonstrated that the protection of FKBP12.6 on AngII-induced cardiac hypertrophy was involved in reducing the concentration of intracellular Ca2+ ([Ca2+]i), in which the protein significantly inhibited the key Ca2+/calmodulin-dependent signalling pathways such as calcineurin/cardiac form of nuclear factor of activated T cells 4 (NFATc4), calmodulin kinaseII (CaMKII)/MEF-2, AKT/Glycogen synthase kinase 3β (GSK3β)/NFATc4 and AKT/mTOR signalling pathways. Our study demonstrated that FKBP12.6 protects heart from AngII-induced cardiac hypertrophy through inhibiting Ca2+/calmodulin-mediated signalling pathways.

KW - Ca signalling

KW - FKBP12.6

KW - angiotensin II

KW - cardiac hypertrophy

KW - transgenic mice

UR - http://www.scopus.com/inward/record.url?scp=85048702021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048702021&partnerID=8YFLogxK

U2 - 10.1111/jcmm.13645

DO - 10.1111/jcmm.13645

M3 - Article

C2 - 29682889

AN - SCOPUS:85048702021

VL - 22

SP - 3638

EP - 3651

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

IS - 7

ER -